Cryoport(US:CYRX)2026-03-03 22:10Revenue Growth - FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance, representing a 12% year-over-year growth[5]. - Life Sciences Services revenue grew 18% year-over-year to $96.5 million, with BioStorage/BioServices revenue rising 22% to $18.4 million[5][20]. - Revenue from commercial cell and gene therapy support increased 29% year-over-year to $33.4 million, with the company supporting a record 760 global clinical trials[3][12]. - Full-year 2026 revenue guidance is set at $190 million to $194 million, indicating an expected growth of 8% to 10% year-over-year[5][9]. - Total revenue for the three months ended December 31, 2025, was $45.450 million, compared to $41.452 million for the same period in 2024, representing a year-over-year increase of 7.2%[38]. - Life Sciences Services revenue for the year ended December 31, 2025, was $96.497 million, up from $82.044 million in 2024, reflecting a growth of 17.7%[38]. - Life Sciences Products revenue for the year ended December 31, 2025, reached $79.680 million, compared to $74.725 million in 2024, indicating a growth of 6.5%[38]. Profitability and Loss - Net income for FY 2025 was $78.3 million, primarily driven by the divestiture of the CRYOPDP business, compared to a net loss of $114.8 million in FY 2024[27]. - The Company reported a net loss of $11.644 million for the three months ended December 31, 2025, compared to a net loss of $18.669 million for the same period in 2024[38]. - The loss from operations for the year ended December 31, 2025, was $36.806 million, a significant improvement from a loss of $121.671 million in 2024[38]. - For the year ended December 31, 2025, GAAP net income was $78.301 million, compared to a loss of $114.756 million in 2024[45]. - Adjusted net loss for the three months ended December 31, 2025, was $8.521 million, an improvement from a loss of $18.670 million in the same period of 2024[45]. - Adjusted EBITDA from continuing operations for the year ended December 31, 2025, was a loss of $5.779 million, compared to a loss of $17.771 million in 2024[46]. - The company reported a GAAP loss from continuing operations of $33.969 million for the year ended December 31, 2025, compared to a loss of $104.708 million in 2024[46]. Cost Management - Operating costs for FY 2025 decreased to $119.9 million from $191.3 million in FY 2024, reflecting a significant reduction in expenses[21]. - GAAP operating costs and expenses for the year ended December 31, 2025, were $119.860 million, down from $191.328 million in 2024[44]. - Non-GAAP adjusted operating costs and expenses for the year ended December 31, 2025, were $127.519 million, compared to $119.860 million in 2024[44]. Financial Position - The company held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025[25]. - Cash and cash equivalents as of December 31, 2025, were $250.494 million, an increase from $34.000 million in 2024[39]. - The company had total current assets of $476.174 million as of December 31, 2025, compared to $571.000 million in 2024[39]. - Total liabilities as of December 31, 2025, were $262.351 million, compared to $703.492 million in 2024[39]. - Total stockholders' equity as of December 31, 2025, was $502.638 million, compared to $1.000 million in 2024[39]. Strategic Initiatives - Cryoport formed a strategic partnership with DHL Group, enhancing its positioning in the EMEA and APAC regions[8]. - The company launched a Global Supply Chain Center in Paris and expanded operations in Belgium to support key commercial clients[7]. - The Company plans to expand its global partnerships and expects revenue contributions from IntegriCell's cryopreservation service centers throughout 2026[36]. - The Company anticipates potential impacts on its business from external factors such as supply chain constraints and inflationary pressures[28]. - The Company will host a conference call on March 3, 2026, to discuss its financial results and future outlook[31].